# Truveta

> Truveta is a health-system-owned healthcare data and intelligence company. It converts de-identified US patient records into continuously updated research data, AI-assisted analysis, and evidence services for life sciences, healthcare, academic, and government organizations. Its Genome Project is designed to connect consented genetic information with longitudinal clinical records.

- **Founded:** 2020
- **Headquarters:** Bellevue, United States
- **Founders:** Terry Myerson (Co-founder; former CEO, retired September 2026), Jay Nanduri (Co-founder, CTO and interim co-CEO), Ryan Ahern (Co-founder, Chief Medical Officer and interim co-CEO), Providence (Founding health system), Advocate Health (Founding health system, identified by current name), Tenet Healthcare (Founding health system), Trinity Health (Founding health system)
- **Products:** Truveta Data, Truveta Studio / trusted research environment, Truveta Tru, Truveta Genome Project, Truveta Live Link
- **Notable:** 2024 JAMA Internal Medicine publication comparing tirzepatide and semaglutide using routine-care records., September 2026 company account reports more than 140 million patient journeys and more than 1,000 scientific citations of research using its data., Raised US$320 million in January 2025; reported cumulative funding US$515 million.

## Products & services

- **Truveta Data** — Daily-updated, de-identified longitudinal EHR data linked with claims, mortality and social drivers of health; supports clinical notes and imaging research.
- **Truveta Studio / trusted research environment** — Cohort creation, notebooks, reusable definitions and reproducible study workflows with provenance and audit controls.
- **Truveta Tru** — Generative AI research assistance for population building, clinical code sets and exploratory analysis.
- **Truveta Genome Project** — Consented biospecimen program linking genetic and clinical data; RGC agreement covers sequencing up to ten million volunteers. This is a project target.
- **Truveta Live Link** — Connects customer-owned datasets with daily-updated clinical records for prospective research, with secure storage and expert determination.
- **Truveta Intelligence** — Natural-language questions and inspectable analyses grounded in current real-world clinical data; announced April 28.
- **Truveta Evidence Services** — Expert support for study design, execution and regulatory evidence generation.

## Achievements

- 2024 JAMA Internal Medicine publication comparing tirzepatide and semaglutide using routine-care records.
- September 2026 company account reports more than 140 million patient journeys and more than 1,000 scientific citations of research using its data.
- Raised US$320 million in January 2025; reported cumulative funding US$515 million.
- Published a technical description of its data platform in JAMIA Open in 2026.
- A September 2026 company case study describes an FDA-approved device label expansion supported by its real-world evidence.

## Latest updates

- **2026-09** — Myerson retired September 15; Nanduri and Ahern became interim co-CEOs while the board searches for a successor.
- **2026-09** — Published a case study on FDA-approved device label expansion using real-world evidence.
- **2026-08** — Published a peer-reviewed platform overview in JAMIA Open.
- **2026-04** — Launched Truveta Intelligence April 28 for Data subscribers.
- **2026-01** — Announced Live Link January 13 for prospective data linkage.

## Links

- Website: https://www.truveta.com/
- LinkedIn: https://www.linkedin.com/company/truveta
- Twitter/X: https://twitter.com/truveta
- YouTube: https://www.youtube.com/@truveta
- Instagram: https://www.instagram.com/truveta/
- Facebook: https://facebook.com/TruvetaHealth

---

Profile page: https://yespress.io/truveta
Published by YesPress — https://yespress.io
Last updated: 2026-10-06